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This study was to investigate the neuroprotective effect of curcumin against inflammation-mediated 
dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model 
of Parkinson’s disease (PD). Curcumin loaded sodium hyaluronate based mucoadhesive microemulsion 
(CMME) was developed by using Box Behnken design of Response surface method (RSM) and was 
characterized. Male C57BL/6 mice were first treated with four intraperitoneal injections of MPTP (20 
mg/kg of body weight) at 2 h intervals followed CMME intranasal administration for 14 days at 2.86 
mg of curcumin/kg of body weight per once a day. Optimal CMME containing 3% Capmul MCM as 
oil phase, 37 % of Accenon CC and Transcutol HP at 2.5:1 ratio and 0.5% sodium hyaluronate was 
stable, non-ciliotoxic with 57.66 nm±3.46 as average globule size. PdI value (0.190 ± 0.19) and TEM 
result depicted the narrow size distribution of CMME.All three independent variables had a significant 
effect (p<0.05) on the responses and the designed model was significant for all taken responses. In-vivo 
results revealed significant reduction of MPTP-mediated dopamine depletion after nasal administration of 
CMME. MPTP intoxication significantly decreased striatal DA content to 21.29 % which was then elevated 
to 55.37% after intranasal curcumin treatment. Significant improvement in motor performance as well 
as gross behavioural activity of mice was observed from rota-rod and open field test findings. Findings 
of the investigation revealed the symptomatic neuroprotection of curcumin against MPTP-induced 
neurodegradation in the striatum and hence could be considered as a promising approach to treat PD.
Uniterms: Curcumin/neuroprotective effect. Response surface methodology (RSM). Box-Behnken 
design. Sodium hyaluronate. Neurodegradation. Parkinson’s disease/treatment. Male mice C57BL/6 
INTRODUCTION
Neuroinflammation may contribute to the 
progressive dopaminergic neuronal loss in substantia 
nigra pars compacta (SNPS) of brain that has been 
observed in some experimental models of Parkinson’s 
disease (PD), the second most common neurodegenerative 
disorder after Alzheimer’s disease characterised by a slow 
and progressive degeneration of dopaminergic neurons 
in the substantia nigra (Lindvall et al., 2003; Hirsch, 
Hunot, 2009). Although the etiology of PD remains 
inscrutable, but some recent advancement reveals the 
direct involvement of inflammation and oxidation of 
inflamed substantia nigra pars compacta (SNPS) on 
the PD. PD pathogenesis specifically involved severe 
dopaminergic neuronal degeneration in the substantia 
nigra pars compacta (SNpc) and striatum. 
In order to understand the pathophysiology of PD, 
neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) which produces parkinsonian syndrome in 
humans, primates and rodents provides better can be 
used. MPTP is enzymatically converted into its toxic 
metabolite MPP+ (1-methyl-4-phenylpyridinium) by the 
enzyme monoamine oxidase-B (MAO-B), primarily in 
astrocytes of brain and is known to specifically damage 
dopaminergic neurons in the SNpc (Reznichenko et al., 
2010). The neurotoxic effect of MPP+ primarily involves 
the disruption of oxidative phosphorylation and redox 
homeostasis along with elevation of intra-cellular Ca2+ 
levels and inflammatory responses (Esposito et al., 
2007; Douna et al., 2012). The dopaminergic neuronal 
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cell death is due to the inflammatory cascade including 
microglial activation and excessive secretion of cytotoxic 
agents like pro-inflammatory cytokines and free radicals. 
So, considering the importance of inflammation in PD 
progression, neuroprotective and anti-inflammatory 
strategies may offer a promising therapeutic intervention 
for the treatment and management of PD. 
Curcumin, the principal curcuminoid of turmeric, 
has been shown to exhibit antioxidant as well as anti-
inflammatory. However, the clinical usefulness of curcumin 
is limited by its poor water solubility and high first-pass 
metabolism leading to low oral bioavailability and poor 
brain entry due to over expression of p-glycoprotein 
(Brown et al., 2012; Miller, Bauer, Hartz, 2008). 
Therefore, it is worthwhile to develop an alternative but 
effective approach to improve therapeutic effect of this 
nontoxic and potent phytoconstituent. 
Recently, nasal route becomes one of the most 
versatile routes of drug administration because it offers 
several advantages including rapid absorption of drug, 
avoidance of hepatic first-pass metabolism and more 
precisely drug delivery preferentially to brain via the 
olfactory region through nasal turbinates olfactory and 
trigeminal nerve pathways (Barakat, Omar, Ahmed, 2006). 
Therefore, the nasal route may provide a better alternative 
to oral or intravenous administration for the brain delivery 
of Curcumin. 
However, nasal delivery of Curcumin may have 
several challenges like effective nasal delivery volume and 
anti-inflammatory dose of Curcumin is very high i.e., 2.86 
mg/kg of body. Secondly thenatural defense mechanism 
i.e., nasal mucociliary clearance and metabolism in 
nasal mucosa (Piaoa et al., 2010). So, formulation like 
microemulsion may be effective which can improve the 
solubility of poorly water-soluble Curcumin which can 
accommodate the effective dose in human i.e., ≤400 μL 
(200 μL/nostril). Viscosity of the formulation may play a 
vital role in prevention of its rapid nasal clearance.
Microemulsions are thermodynamically stable and 
isotropic systems of oil, water, surfactant and cosurfactant 
mixture with a droplet size usually in the range of 10-100 
nm. These systems, by virtue of their low globule size 
and ability of improving aqueous solubility of poor water 
soluble drug like Curcumin, are widely explored as nasal 
drug delivery system to enhance CNS uptake (Patel, 
Mandal, Rajesh, 2012). Addition of mucoadhesive agent 
such as a polyelectrolyte polymer further helps to increase 
the retention time due to the electronic interaction between 
mucin of nasal mucosa and the polymer of formulation 
which in turn further facilitates the absorption (Elshafeey, 
Bendas, Mohamed, 2009; Harris et al., 1988). Evidences 
of intranasal drug delivery systems formulated using 
mucoadhesive agent and its benefits in enhancing nose-
to-brain drug transport have been reported in various 
literatures (Pathak et al., 2014; Mandal, Mandal, 2010). 
Also, several literatures revealed that targeting brain 
through nasal route is possible due to the unique nose-
to-brain connection (Tomoyuki et al., 2007). Also for the 
intranasal delivery, an optimal formulation with minimum 
number of experiments and low globule size to provide 
higher % release, an adequate permeation rate in a short 
time is required. 
Thus, RSM with Box-Behnken design was used 
in this study to obtain the optimal CME and evaluate the 
influence of formulation composition and their proportion 
on drug permeation capacity through sheep nasal mucosa 
(Chopra et al., 2007; Gannu, Rao, 2012). In this study, the 
amounts of oil (X1), mixture of surfactant and cosurfactant 
(X2) and aqueous solution of sodium hyaluronate (X3) 
were selected as independent variables. The Box-Behnken 
design was used to investigate the main effects, interaction 
effects and quadratic effects of the individual independent 
factors on average globule size (Y1), polydispersity index 
(PdI) (Y2), flux (Y3), viscosity (Y4) and % drug release 
after 10 h (Y5). CMME may result in effective nose-
to-brain transport and greater distribution of curcumin 
within and into the brain which may help to maximize 
the therapeutic index of the drug and may open newer 
approach of treating PD.
In our previous study the dissolution of Curcumin 
was enhanced through the developed microemulsion 
(Mandal, Mandal, Patel, 2013). Hence, the objective 
of this investigation is to explore the unique nose to 
brain connection through the optimal CMME and also 
to perform the comparative neuroprotective effect of 




Curcumin was received as a gift sample from Arjuna 
Natural Extracts Pvt. Ltd., Hyderabad, India. Cremophor 
RH 40 and Cremophor EL were obtained from Colorcon 
Asia (Mumbai, India). Labrafac CM10, Transcutol HP, 
Transcutol P, Maisine 35-1, Labrafil M 1944 CS and 
Labrafac PG were received as gift sample from Gattefosse, 
France. MPTP-HCl was purchased from Sigma-Aldrich 
(St. Louis MO, USA).Capmul MCM, Capmul MCM EP, 
Accenon CC, Captex-355 and Labrafac were procured 
as gift sample from Abitec Corporation, Jackson St 
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Janesville, USA. Isopropyl myristate, Tween 60, Isopropyl 
alcohol, Acetonitrile and Methanol wereboughtfrom 
Gujaratchemicalcorporations (Vadodara,India). Sodium 
hyaluronate, Oleic acid, Tween-60, Ethyl oleate and PEG 
400 were bought from Chemdyes (Mumbai, India). All 
other chemicals were reagent grade. 
METHODS
Selection of formulation compositions
For o/w microemulsion, selection of oil as internal 
phase was mainly based on the drug solubility capacity and 
biocompatibility as mentioned in the literature (Mandal, 
Mandal, 2010). Different oils like isopropyl myristate, 
Capmul MCM EP, Capmul MCM Labrafac PG, Oleic 
acid, Labrafil M 1944CS and Labrafil M 2125CS were 
screened for drug solubility study. Selection criteria for 
surfactant were its HLB value, drug solubility and non-
toxic nature. Surfactants having HLB value ranging in 
between 12 to 18 like Tween-60, Tween-80, Captex-355, 
Accenon CC and Cremophor EL were screened for drug 
solubility study. Screening of co-surfactants was based 
on their ability to form stable and clear microemulsion at 
a minimum concentration and several co-surfactants like 
ethanol, Isobutyl alcohol, isopropyl alcohol and Transcutol 
HP were screened. The pseudo-ternary phase diagrams 
of oil, surfactant: co-surfactant (Smix) and water were 
developed using distilled water titration method (Mandal, 
Mandal 2010). The mixture of oil and at different ratio of 
Smix (1:1, 1.5:1, 2:1, 2.5:1, 3:1 and 3.5:1) at certain volume 
ratio were titrated with distilled water in drop wise manner. 
Using Chemix software, microemulsion regions were 
determined and Smix showing maximum microemulsion 
region was used for the development of microemulsion 
(Mandal, Mandal, 2010). 
Preparation of formulations
Box-Behnken design was used to develop CMMEs 
in which three different independent variables i.e., amount 
of Capmul MCM (X1), Smix (Accenon CC: Transcutol HP, 
X2) and amount of sodium hyaluronate (X3, in terms of % 
w/v) with their levels was set according to the preliminary 
experiments. A suitable polynomial model was selected 
based on the significant terms (p<0.05), the least 
significant lack of fit, the multiple correlation coefficient 
(R2) and adjusted multiple correlation coefficient (adjusted 
R2) provided by Design-Expert® software (Stat-Ease, Inc., 
Minneapolis, Minnesota, USA) (Gannu et al., 2010). The 
default model in the design of the experimental space was 
quadratic and the upper and lower levels are demonstrated 
in Table I.
On the basis of the Box-Behnken design model 
provided by Design-Expert® Software (Stat-Ease, 
Inc., Minneapolis, Minnesota, USA), a total 15 model 
CMMEs were randomly arranged. The compositions 
of all model CMMEs are summarized in Table I. Smix 
(2.5:1 of Accenon CC and Transcutol HP) was mixed 
well with drug dissolved Capmul MCM part. The above 
mixture was then titrated with different aqueous sodium 
hyaluronate concentration with mild and continuous 
stirring by magnetic stirrer at room temperature (Mandal, 
Mandal, Patel, 2013) and finally average globule size, 
polydispersity index (PdI), Flux, viscosity and % drug 
release after 10 h were determined. Curcumin solution 
(CPG, 3 mg/mL) was prepared by addition of Curcumin 
(30 mg) to 8 mL of distilled water and ethanol (6:4) with 
continuous stirring. The pH was adjusted to 6.8 ± 0.25 
using glacial acetic acid (approximately 0.06 mL/mL). 
The mixture was stirred for 10 min and a clear solution 
was obtained. Final volume was made up to 10 mL using 
distilled water. pH of the final formulations was also 
checked. 
Optimization
Responses like average globule size, polydispersity 
index (PdI), Flux, viscosity and % drug release after 
10 h were selected for both numerical and graphical 
optimization. It was decided to choose maximization for 
flux, % release and minimization for average globule 
size and PdI with suitable viscosity in order to obtain an 
optimized formulation. On a contour plot, visually search 
for the best compromise which stands for the formulation 
with desirable values for all responses were visually 
searched. Finally, for verification, three optimized CMME 
batches were prepared experimentally and the responses 
i.e., average globule size, polydispersity index (PdI), 
flux, viscosity and % drug release for all the batches were 
determined. Flux i.e., amount of drug release per area of 
permeation was quantified from the ex vivo permeation 
study through sheep nasal mucosa.
Evaluation of dependent variables
Globule size and Zeta potential of CMMEs were 
determined by Zetasizer (Nano ZS; Malvern Instruments 
Inc, Malvern, UK). The viscosity of CMMEs determined 
using Brookfield viscometer (HVDVII, USA). The 
sample was sheared using spindle no. 43 at 30 rpm and at 
room temperature. Data was taken after 30 s of viscosity 
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measurement. All experiments were repeated three times 
(Mandal, Mandal, 2010). 
In vitro comparative release of Curcumin from 
CMME and CPG was performed using USP-II dissolution 
apparatus. 10 ml of CMME (≈ 30 mg of curcumin) was 
taken in dialysis membrane (10,000 D) and was kept in 
900 ml of the dissolution medium i.e., phosphate buffer 
(pH-6.4) at 37 ± 0.5 °C and 50 rpm (Mandal, Mandal, 
Patel, 2013). At predetermined time interval, aliquots of 
5ml in each test time point was withdrawn from receptor 
compartment and replaced with same amount of freshly 
prepared dissolution medium equilibrated at 37 ± 0.5 °C. 
The samples were the analysed for drug release by UV-VIS 
Spectrophotometer (Mandal, Mandal, Patel, 2013). 
Comparative permeability of CMME and CPG 
through excised sheep nasal mucosa was determined 
using Franz diffusion cell having an effective diffusion 
area of 12.56 cm2 and volume 25 mL (Patel, Mandal, 
Rajesh, 2012). The prepared nasal mucosa of 12.56 cm2 
was mounted on to the receptor compartment having 25 
mL of diffusion medium (Saline phosphate buffer, pH-6.4) 
for 15 min. The donor compartment was fixed to it and was 
loaded with formulations (≈ 6 mg of curcumin). Diffusion 
was done at 37 ± 0.5 °C and 50 rpm. At predetermined 
intervals, up to 10 h, aliquot of 0.5 mL was withdrawn 
from the receptor medium and was analyzed by UV-VIS 
Spectrophotometer (Mandal, Mandal, 2010; Mandal, 
Mandal, Patel, 2013). Each data point represented the 
average of three determinations. Flux i.e., % drug release 
per unit area of the sheep nasal mucosa per unit time was 
also determined. 
Data analysis
The formulation variables i.e., Independent variables 
(X1, X2 and X3) and responses or dependent variables 
(average globule size, PdI, viscosity, flux and % drug 
release) of all CMMEs were treated by the Design-
Expert®software. The linear, quadratic, and cubic models 
was used to describe the relation between independent 
and dependent variables for the constrained mixture 
designs consisting of three components. The significant 
terms were set at a p- value of less than 0.05. The suitable 
fitting model was selected based on the comparisons of 
TABLE I - Details of the levels, compositions and responses of model formulations (CMME) provided by Box-Behnken design 
Batch X1 X2 X3 Avg. GlobuleSize (nm) 
PdI





F1 0.10 1.55 0.50 55.55 0.192 20.8 25.5 96.1
F2 0.50 1.55 0.50 64.29 0.204 16.2 30.6 83.1
F3 0.10 1.65 0.50 58.88 0.196 21.3 34.6 80.0
F4 0.50 1.65 0.50 54.46 0.302 17.4 31.9 86.2
F5 0.10 1.60 0.25 54.23 0.217 20.4 22.8 90.4
F6 0.50 1.60 0.25 65.78 0.193 22.3 31.7 76.4
F7 0.10 1.60 0.75 79.89 0.363 19.6 36.2 86.2
F8 0.50 1.60 0.75 88.79 0.382 19.1 39.3 79.3
F9 0.30 1.55 0.25 58.64 0.202 21.4 29.5 85.8
F10 0.30 1.65 0.25 52.61 0.198 27.2 35.5 90.4
F11 0.30 1.55 0.75 72.44 0.344 22.3 33.9 87.3
F12 0.30 1.65 0.75 61.16 0.264 26.0 34.1 85.7
F13 0.30 1.60 0.50 52.47 0.214 22.1 31.9 88.3
F14 0.30 1.60 0.50 53.11 0.201 22.3 31.8 88.6
F15 0.30 1.60 0.50 52.49 0.186 22.4 32.6 88.1
Low Medium High 
X1= Capmul MCM (Oil) (mL) 0.1  0.3 0.5
X2= Acenon CC: Transcutol HP (Smix) 1.55 1.60 1.65
X3= % Sodium hyaluronate 0.3 0.5 0.7
The amount of Curcumin was 30 mg. Total volume of CMME containing Capmul MCM (X1), 3.5 ml of each Smix (X2), and % 
Sodium hyaluronate(X3) was 10 mL.
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several statistical parameters including the p- value of the 
model (p-value must be less than 0.05), p-value of lack 
of fit (p-value must be greater than 0.05), the multiple 
correlation coefficient (R2), adjusted multiple correlation 
coefficient (adjusted R2), and the coefficient of variation 
proved by the Design-Expert® software (Chopra et al., 
2007; Gannu, Rao, 2012).
Nasal ciliotoxicity
Nasal ciliotoxicity studies were carried out using 
excised sheep nasal mucosa. In brief, excised sheep nasal 
mucosa except septum was collected from slaughter 
house in saline phosphate buffer (pH 6.4). Then three 
different nasomucosal parts (S1, S2 and S3) having same 
thickness were mounted on Franz diffusion cell and 
then were exposed with 2 ml of CMME (Test sample, 
2.86 mg/mL curcumin), saline (Negative control) and 
isopropyl alcohol, a serious nasal mucociliary toxicity 
agent (Positive control) for 2 h respectively. All three nasal 
samples were rinsed with distilled water. The mucocilia 
was then examined with an optical microscope (Nikon 
Fx-35A, Japan) after the sample stained with hematoxylin 
and eosin (Mandal, Mandal, 2010). 
In-vitro mucoadhesion study
The mucoadhesive potential of developed nasal 
formulations in terms of residence time was evaluated by 
the reported method (Pathak et al., 2014). Briefly, 100 mg 
of CPG and CMME was placed at the center of separate 
agar plates (1% w/w, prepared in PBS, pH 6.4). After 5 
min, the agar plates were attached to USP disintegration 
test apparatus and moved up and down in PBS at 37 °C 
± 1. The time taken by the formulations to separate from 
the agar plates was noted visually as residence time of the 
formulations.
In vivo experimental study
All animal experiments were approved by the 
Institutional Animal Ethical Committee (CPCSEA No. 
984/14/10/CPCSEA), Government of India, New Delhi, 
India. Male C57BL/6 mice (20-25 g; 8-12 weeks old) were 
used in the present study. The mice were maintained at 
temperature (25 ± 2 °C) and humidity (45 ± 5%) and were 
supplied with standard laboratory diet and reverse osmosis 
(RO) water ad libitum on a 12 h light/dark cycle. Mice were 
assigned to five groups with six animals in each group. 
Group I - Saline treated (Normal control).
Group II - MPTP control (4×20 mg/kg/day). 0.2% of 
MPTP-hydrochloride was prepared using 0.9 % w/v NaCl 
solution. Four doses of 20 mg/kg MPTP solution (total 
dose of 80 mg/kg of body weight) at two hour intervals 
were administered through intraperitoneal route. 
Group III- Intranasal administration of optimized 
CMME at 2.86 mg of curcumin/kg of body weight for 
14 consecutive days to already MPTP (4×20 mg/kg/day) 
treated animal in the same above method (as described 
for Group II).
Group IV- Animals were first treated with MPTP (4×20 
mg/kg/day) in the same above method followed by 
intranasal applied plain drug solution (CPG) at 2.86 mg 
of curcumin/kg of body weight for 14 consecutive days. 
Group V- Animals were treated with only 2.86 mg of 
curcumin/kg of body weight for 14 consecutive days.
35-40 μL of the developed nasal formulations 
containing curcumin equivalent to 2.86 mg/kg were 
administered intranasally with the help of a micropipette 
(200 μL) attached to low density polyethylene tubing with 
internal diameter 0.1 mm at the delivery site (Elshafeey 
et al., 2009). Ventral mid brain and striatum of the three 
experimental animals was dissected on 15th day and 21st 
day of study after euthanized with ketamine and then 
the brain tissues were preserved at -80± 1 °C for further 
investigation. 
Determination of muscular coordination by Rota-
rod test
The motor coordination activity was assessed by 
rota-rod apparatus (Baroda Pvt. Ltd. India) as described 
in the literature (Hiromi et al., 2010). The instrument was 
divided into four compartments and has a rotating rod of 
30 mm diameter. The rotation speed of the rod was set at 
20 rpm and four mice at a time were tested for the total 
duration of 180 s. The apparatus was designed to record the 
time automatically when a mouse falls off from the rotating 
shaft. The time in seconds spent on the rod was recorded 
(retention time) for each mice and the average was used as 
a measure of motor function at 15th and 21st day.
Assessment of gross behavioural activity by open 
field test
The open field test was performed as described in 
the literature (Basso, Beathie, Bresnahan, 1995; Holcomb 
et al., 2006). The open-field apparatus consists of a box 
(26×26×39 cm) with clear plexi-glass walls and floor. 
Briefly, the animals were placed in the centre of a box 
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with the floor lined by equal segments, and the motor (the 
number of crossed segments) activity was monitored for 5 
min. An automated sensor system, consisting of 16 photo 
beams per side measured the fine movement, expressed 
as total ambulation time at 15th and 21st day. 
Quantification of dopamine and its metabolites in 
brain by HPLC
The assay of dopamine (DA) and its metabolites like 
dihydroxyphenyl acetic acid (DOPAC) and homovanillic 
acid (HVA) was quantified by using HPLC-fluorescence 
detection as described in the literature (Liu, Ma, Shi, 
2006; Barbiero et al., 2011). Briefly, striatum after was 
homogenized in phosphate buffer (pH-6.4) in tissue 
homogeniser and the homogenate was centrifuged at 
15,000 rpm (-4 °C) for 300 min. 20 μL samples i.e., 
filtered supernatant through 0.45 μm membrane filter 
was injected on the column. The mobile phase was 
consisted of acetonitrile and 0.1% orthophosphoric acid 
(50:50 v/v). The mobile phase flow rate was set at 1 mL/
min. The DA, DOPAC and HVA signals were detected at 
282 nm and 324 nm as the excitation wavelength and an 
emission wavelength respectively. The quantification of 
DA, DOPAC and HVA was carried out by measuring the 
chromatographic peak areas and results were expressed 
as micrograms per gram wet tissue at 7th day as well as 
15th day.
Statistical analysis
All data are reported as mean ± SD and the difference 
between the groups were tested using Student’s t-test at 
the level of P<0.05. More than two groups were compared 
using ANOVA and differences greater at P<0.05 were 
considered significant. 
RESULTS AND DISCUSSION
Selection of formulation composition and 
formulation development
Capmul MCM was selected as internal phase due 
to its non-toxicity to nasal mucosa and relatively more 
Curcumin solubilising capacity. Accenon CC basing on 
its HLB value with minimum drug solubility was selected 
as surfactant. This was done with an intention to obtain 
more trafficking of drug to obtain more sustained release. 
Transcutol HP was selected as cosurfactant since with 
minimum concentration it developed stable microemulsion 
and also due to the biocompatibility to nasal mucosa and 
compatibility to other formulation compositions including 
Curcumin as determined through FTIR. 
Results of Pseudo-ternary phase diagrams showed 
that formulation with Smix (2.5:1) was having more 
microemulsion existing zone. Hence, from the drug 
solubilising and pseudo-ternary phase diagrams data, 
Capmul MCM, Transcutol HP and Accenon CC were 
selected as oil phase, co-surfactant and surfactant 
respectively to develop microemulsion. 
In order to quantify the effect of independent 
variables on the permeation parameters and the properties 
of CMMEs, the values of the dependent variables (average 
globule size, PdI, viscosity, flux and % release) and three 
independent variables Capmul MCM concentration (X1), 
concentration of Smix (X2) and concentration of aqueous 
sodium hyaluronate solution (X3) were statistically 
analyzed based on the RSM, using a computer program 
provided by the Design- Expert® software. The results of 
multiple regression analysis are summarized in Table II. 
The probability (p-value) of the models was less 
than 0.05 and the p-value of the lack of fit was greater 
than 0.05, indicating that the selected model could well 
TABLE II - Statistical parameter of responses determined by multiple regression Regression Analysis
Regression Coefficient
Coefficient Estimate
Globule size PdI Viscosity Flux % Release
Capmul MCM (X1) 5.14 2.38 0.87 0.87 -4.56
Smix (X2) -8.32 -1.23 -1.66 1.25 +1.87
% Sod. hyaluronate (X3) 7.77 4.23 2.33 -1.12  -2.77
Model (p Value) 0.0003 0.0014 <0.0001 0.0212 <0.0001
Coefficient of variation 2.28% 3.09% 1.33% 8.40% 0.86%
R2 0.987 0.977 0.999 0.928 0.999
Adjusted R2 0.964 0.935 0.998 0.799 0.997
Lack of Fit (p Value) 0.0540 0.0917  0.289 0.877 0.0580
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describe the relationship between the independent and 
dependent variables. The values of the coefficients X1, 
X2 and X3 were represented to the effect extent of these 
independent variables on the response. The relationship 
between the independent and dependent variables was 
elucidated using response surface plots. It was also found 
that average globule size, PdI, viscosity, flux and % release 
of Curcumin was remarkably influenced by the main effect 
and interaction effect of various independent variables as 
shown in Table II.
Analysis for all responses showed that quadratic 
model was the most suitable one (p<0.05). By running 
ANOVA, the final equations for all responses i.e., Globule 
size, PdI, Viscosity, Flux and % Release in their respective 
coded values (A, B and C) were obtained as follows. 
The statistical analysis showed that A, B, C and their 
interactions are significant model terms for response 1 
(Globule size) and response 2 (PdI), C is significant model 
terms for response 3 (viscosity) and B are significant 
model terms for response 4 (Flux) and A, C, AC are 
significant model terms for response 5 (% Release).
Globule Size = + 154.84 + 5.14 × A – 8.32 × B + 
7.77 × C + 1.86 × (A × B) + 1.79× (B × C) + 
9.84 × (A × C) + 3.15 × A2 – 0.98 B2 + 5.47 × C2  (1)
The globule size of microemulsion formulation is a 
crucial parameter as because it influences drug release rate 
and hence the in vivo profile of the drug. From equation 1, 
globule size was influenced by oil, Surfactant-cosurfactant 
concentration ratio (Smix) and mucoadhesive polymer. 
This may be due to the fact that Smix at its increased 
concentration could able to reduce the interfacial tension 
between oil and aqueous phase. But at higher amount 
of oil with same Smix concentration, the lipophilicity of 
oil was not completely being masked by Smix resulting 
into more interfacial tension and increased globule size. 
Mucoadhesive polymer also found to increase the globule 
size which may be due to the fact that it was capable 
of absorbing water and swell which in turn disturb the 
hydrophilic-lipophilic balance of the system. 
PdI Value = + 74.79 + 2.38 × A – 1.23 × B + 4.23 × C + 
0.86 × (A × B) + 1.33 × (B × C) + 6.79 × (A × C) + 
0.97 × A2 – 0.98 B2 + 0.86 × C2  (2) 
Polydispersity index (PdI) indicates the particle 
size distribution of the formulation. Smix was capable 
reducing the interfacial tension between Capmul MCM 
and external aqueous phase as shown in equation 2. The 
effect of stabilizers concentration on particle size and PdI 
value of CMME is depicted in equation 2. Both the particle 
size and PdI value decreased first and then increased 
with the increase of Smix concentration which may be due 
to destabilisation of the system due to the stabilization 
effect. However, the surface area of microemulsion 
particles is limited, resulting in a limited amount of 
stabilizer adsorbed. In addition, excess surfactants tend to 
form micelles and increase solubility of water insoluble 
Curcumin, which may lead to Ostwald ripening, resulting 
in an increase in particle size and PdI. 
Viscosity = + 35.14 + 0.87 × A– 1.66 × B + 2.33 × C – 
1.12 × (A × C) – 0.59 × A2 + 1.44 × C2 + 1.89 ×  
(A × C)  (3)
Microemulsion viscosity increased with an increase 
in oil and mucoadhesive polymer concentration as 
shown in equation 3. This may be due to the fact that 
mucoadhesive polymer absorbs aqueous part of the 
formulation and swelled. Free water concentration reduced 
and hence viscosity of the microemulsion automatically 
increased. Interaction effect of Capmul MCM and % 
sodium hyaluronate got positive effect while interaction 
of oil and mixture of surfactant and cosurfactant showed 
opposite effect to that of mucoadhesive polymer alone. 
Flux = + 45.61 + 0.87 × A + 1.25 × B – 1.12 × (C) + 
0.78 (A × B)– 1.47 (A × C)  (4)
Oil (A) and Smix (B) concentration showed relatively 
significant effect on flux as shown in equation 4. Accenon 
CC and Transcutol HP reduce the globule size and 
hence surface area increased which in turn increases the 
permeation rate through nasal mucosa or flux by altering 
the fluidization of lipid of the nasal mucosal layer. As 
mentioned above, the average globule size of CMME 
influences drug release rate and absorption. 
% Release = + 134.4 – 4.56 × A + 1.87 × B – 2.77 × C 
+ 0.55 × (A × B) – 1.83 × (A × C) + 0.71 × (B × C) + 
1.41× A2 -0.89 × C2  (5) 
Drug release from the formulation was heavily 
but negatively influenced by Capmul MCMand sodium 
hyaluronate, while Accenon CC and Transcutol HP showed 
positive effect as shown in the equation 5. Capmul MCM 
and sodium hyaluronate concentration in the formulation 
reduced the drug release from the formulation which may 
be due to their reservoir property of oil and enhanced 
viscosity due to polymer. Surfactant and cosurfactant 
concentration increases the drug release due to their water 
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solubility enhancing property of poorly water soluble 
drugs like curcumin. The aim of optimization was to 
obtain the defined targets for all responses simultaneously 
with respect to the predefined constraints. Overlay plots 
of all responses for predicted formulations are depicted 
in Figure 1.
The grey region stands for formulations with 
minimum globule size, maximum release and maximum 
flux. In order to confirm the desirability of provided 
optimized formulations, five formulations were prepared 
experimentally and all five responses i.e., average 
globule size, PdI, viscosity, flux and % release were 
evaluated as given in Table III. It was observed that the 
experimentally obtained data and the predicted responses 
were significantly same and therefore, the optimization 
process was verified. 
CMMEs developed with 0.5% w/v of sodium 
hyaluronate, 0.3 mL Capmul CMC, 3.70 mL of Smix 
(Accenon CC and Transcutol HP at 2.5:1 ratio) showed 
the lowest globule size and PdI, highest flux, optimum 
viscosity and highest drug release as shown in Table IV 
and hence was considered as optimized formulation. This 
was also predicted by the application of experiment design 
methods since the developed CMME showed minimum 
difference between the predicted and observed responses. 
Evaluation of microemulsion formulation
Optimal CMME was found to be transparent, stable 
with viscosity ranging from 40.22×103 cPs to 46.18×103 
cPs at 25 °C with globule size 57.6 ± 3.46 nm as shown 
in Figure 2. Data of Zeta potential was -16.28±2.94 mV 
as shown in Figure 3 indicates stability of formulation 
since no aggregation due to repulsion and attraction will 
be observed. 
Results of globule size and PdI value (0.190±0.19) 
indicates that the formulation was monodisperse and of 
nanosize which may help in the intranasal permeation 
TABLE III - Desirability confirmation of Box-Behnken design through the comparision of predicted and observed results of size, 
PdI, viscosity, flux and % release of CMME
Sr No.
Component Globule size (nm) PdI
Flux  
[µg/ (cm2h)] Viscosity (Ps)
% Release 
(After 10h)
O Smix P Pre. Obs. Pre. Obs. Pre. Obs. Pre. Obs. Pre. Obs.
1 0.30 3.80 0.50 58.6 57.4 0.198 0.208 21.0 19.4 39.8 38.2 95.9 92.6
2 0.31 3.80 0.52 58.4 57.5 0.205 0.216 20.9 20.0 39.5 37.1 91.3 93.0
3 0.31 3.75 0.50 58.9 58.0 0.198 0.202 20.8 20.2 39.5 38.0 94.4 91.6
4 0.30 3.70 0.50 56.7 56.3 0.198 0.195 20.6 21.8 39.3 38.7 92.1 91.8
5 0.30 3.80 0.50 56.6 58.1 0.212 0.227 22.0 2.89 40.2 42.1 87.5 88.9
(Pre.- Predicted and Obs.- Observed)
FIGURE 1 - Overlay plots of response (Globule size, PdI, 
Viscosity, Flux and % Release) of predicted formulation.
FIGURE 2 - Result of average globule size and PdI indicating 
the nanosize with narrow size distribution of developed CMME.
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which is supported by the TEM results as shown in 
Figure 4. 
Viscosity data also confirmed the residence of 
the microemulsion on the nasal mucosa. However, the 
obtained result indicated that the physical properties of 
CMMEs were significantly influenced by the combinations 
of independent variables. 
In vitro release and ex vivo permeation study
Release study showed that 93.81±2.68 % of drug 
was sustained released from CMME for 10 h. From the 
data, it was observed that the release rate was decreased 
with increase amount of independent variables like oil and 
mucoadhesive polymer. This may be due to the fact that 
partitioning of drug was more profound when the amount 
of the internal phase and mucoadhesive polymer were 
increased which in turn due to the solubility of drug in 
these vehicles. This can be explained by Noyes-Whitney 
equation, where the rate of dissolution increases with 
a decrease in the particle size, because of the resultant 
enhancement in the surface area and decrease in the 
diffusion layer thickness. The flux of 22.17 [µg/(cm2 h)] 
revealed the quick permeation through nasal mucosa 
which may be due to the relatively smaller globule size 
and cumulative penetration action of oil, surfactant and 
co-surfactant. The effect of oil, mixture of surfactant 
and co-surfactant and sodium hyaluronate on physical 
properties and drug penetration capacity of microemulsion 
was evaluated by RSM with Box-Behnken design and 
the results indicated that CMME system had a significant 
permeation enhancement effect for intranasal delivery of 
Curcumin. Moreover, the developed system can reduce the 
interface tension between nasal mucosa and vehicle and 
thus, they can achieve a faster permeation which will be 
supported by the viscosity of the formulation.
Nasal ciliotoxicity
Results of nasal ciliotoxicity studies as shown in the 
Figure 5 reveal the non-toxicityeffect of the developed 
CMME and hence it was found suitable for application 
on the nasal mucosa. 
In-vitro mucoadhesion study
The observed retention time for CMME and CPG 
were 17.0±1.5 and 1.5±0.55 min, respectively (n=3). 
The retention time on agar plate showed by CMME was 
FIGURE 3 - Zeta potential of CMME showing its stability 
during storage.
FIGURE 4 - TEM result of the optimized CMME indicating the 
narrow particle size with uniform distribution.
FIGURE 5 - Result of nasociliotoxicity study showing the 
non-toxicity of developed CMME.5[A], 5[B] and 5[C] are 
representative of saline, isopropyl alcohol and developed 
CMME treated mucosal part respectively.
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significantly higher than CPG. Sodium hyaluronate after 
hydration in the nasal ciliary microenvironment forms 
hydrogen bonds with the biological substrates through 
its carboxylic group (Morimoto et al., 1991). Thus, it can 
be concluded that the developed CMME will be able to 
increase the residence time of the formulation on the nasal 
mucosa which can be attributed due to presence of sodium 
hyaluronate (0.5 % w/w) (Horvat et al., 2009; Pathak et 
al., 2014). 
In vivo study 
Determination of muscular coordination and gross 
behavioural activity
Figure 6 depicted significant (p<0.05) reduction in 
motor performance in MPTP group as compared to normal 
control group as well as CPG. Treatment with Curcumin 
(2.86 mg/kg) through CMME in third group of animals 
significantly (p<0.05) improved the muscular coordination 
activity as compared to MPTP-alone group.Further, MPTP 
intoxication resulted in significant (p<0.05) decrease in 
total gross activity as compared to normal control group. 
Intranasal administration of CMME (2.86 mg curcumin 
per kg of body weight) significantly (p<0.05) improved 
the total gross activity when compared to MPTP-alone 
group as shown in Figure 6. although CPG initially showed 
improved muscular coordination and gross behavioural 
activity but subsequently not sustained the proposed 
beneficial effect since only mucoadhesive property of CPG 
on nasal mucosal membrane not able to alter the aqueous 
solubility of curcumin. 
Protective effect of curcumin on gross neurological 
activity as assessed through an open field test. Steep 
reduction in total ambulation time was observed in 
MPTP-intoxicated group as compared to normal controls. 
Curcumin treatment significantly improved the total 
ambulation time as shown in Figure 7.
Quantification of DA and its metabolites
MPTP intoxication significantly (p<0.05) decreased 
striatal DA content to 21.29% (6.53 ± 0.86 μg/g of brain 
tissue) in comparison to normal control (21.29±1.54 μg/g 
of brain tissue ≅100%), which was then elevated to 55.37% 
(13.67±0.58 μg/g of brain tissue) by curcumin treatment. 
In-addition, a concomitant elevation of DA turnover 
was also observed in MPTP induced mice which was 
significantly prevented on curcumin treatment as shown 
in Table IV. 
Neuroprotective effect of curcumin against MPTP 
mediated dopaminergic neuroinflammation. Intranasal 
administration of curcumin significantly protected 
dopamine depletion with concomitant elevation in DA 
turnover compared to MPTP-treated mice. Values are 
expressed as mean ± SD and statistically significant (# 
P<0.05) for normal control V/s MPTP and (* P<0.05) 
MPTP V/s curcumin treated groups (n=6).
These findings suggestive of neuroprotective 
efficacy of curcumin via developed CMME through 
intranasal route. Furthermore, curcumin concentration 
was high in brain tissue for CMME than that of CPG 
(2007 ng/g±37.88 of brain tissue V/s 301.4 ng/g±21.21) 
indicating the suitability of brain delivery of curcumin by 
CMME through nasal route over CPG. The mechanisms 
FIGURE 7 - Protective effect of Ibuprofen on gross neurological 
activity as assessed through an open field test. Values are 
expressed as mean ± SD (n=06 per group.) Normal control v/s 
MPTP (# P< 0.05) and MPTP v/s treated group (** P<0.05).
FIGURE 6 - Protective effect of CMME on motor coordination 
in rota-rod test. Data are expressed as mean ± SD (06 per group). 
#P<0.05 normal control v/s MPTP and **P<0.05 MPTP v/s 
treated group.
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of the protective effects curcumin have been linked with 
inhibition of inflammation coupled with anti-oxidation 
property during the acute phase of MPTP injury. Reactive 
oxygen species (ROS) formation is suggested to be 
involved in progressive dopaminergic neuron damage in 
PD. 
CONCLUSION
In the present investigation, a mucoadhesive 
microemulsion system for intranasal delivery of Curcumin 
was successfully developed and optimized using Box-
Behnken experimental design. The design is valid for 
predicting the globule size, PdI, viscosity, flux and % drug 
release in the formulation optimization. From obtained 
results of above experiment, it can be concluded that 
3% Capmul MCM, 37% of Accenon CC and Transcutol 
HP at 2.5:1 ratio, 0.5% sodium hyaluronate and 30 mg 
of Curcumin, provide optimal globule size of 57.66 nm 
with narrow size distribution and suitable zeta potential 
of –16.28 mV. In vivo studies indicate that mucoadhesive 
property of CMME comparatively helps to increase 
Curcumin uptake into the brain. Curcumin, through 
developed nasal mucoadhesive microemulsion system, 
increases DA concentration significantly in brain which 
in turn improves muscular coordination as well as gross 
behavioural activities of the test animal. Thus, intranasal 
formulation if properly formulated may be considered 
as an effective alternative approach to treat Parkinson’s 
disease. 
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